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Abstract
Background: Late-onset Pompe disease (LOPD) is a recessive disease caused by α-glucosidase (GAA) deficiency,
leading to progressive muscle weakness and/or respiratory failure in children and adults. Respiratory derangement
can be the first indication of LOPD, but the diagnosis may be difficult for pneumologists. We hypothesize that
assessing the GAA activity in suspected patients by a dried blood spot (DBS) may help the diagnosis of LOPD in the
pneumological setting.
Population and methods: We performed a multicenter DBS survey of patients with suspected LOPD according to
a predefined clinical algorithm. From February 2015 to December 2017, 140 patients (57 ± 16 yrs., 80 males) were
recruited in 19 Italian pneumological units. The DBS test was performed by a drop of blood collected on absorbent
paper. Patients with GAA activity < 2.6 μmol/L/h were considered positive. A second DBS test was performed in the
patients positive to the first assay. Patients testing positive at the re-test underwent a skeletal muscle biopsy to
determine the GAA enzymatic activity.
Results: 75 recruited subjects had outpatient access, 65 subjects were admitted for an acute respiratory failure
episode. Two patients tested positive in both the first and second DBS test (1.4% prevalence), and the LOPD
diagnosis was confirmed through histology, with patients demonstrating a deficient GAA muscle activity (3.6 and
9.1 pmol/min/mg). A further five subjects were positive in the first DBS test but were not confirmed at re-test. The
two positive cases were both diagnosed after hospitalization for acute respiratory failure and need of noninvasive
ventilation. Most of the recruited patients had reduced maximal respiratory pressures (MIP 50 ± 27% and MEP
55 ± 27% predicted), restrictive pattern (FEV1/FVC 81.3 ± 13.6) and hypoxaemia (PaO2 70.9 ± 14.5 mmHg). Respiratory
symptoms were present in all the patients, but only 48.6% of them showed muscle weakness in the pelvic girdle and/
or in the scapular girdle (35.7%).
Conclusions: DBS GAA activity test may be a powerful screening tool among pneumologists, particularly in the acute
setting. A simple clinical algorithm may aid in the selection of patients on which to administer the DBS test.
Keywords: Late-onset Pompe disease, Acute respiratory failure, Respiratory high dependency care unit, Noninvasive
ventilation, Diagnosis
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Introduction
Pompe disease (ORPHA#365) is a rare autosomal reces-
sive disease due to alpha-glucosidase (GAA) deficiency,
leading to glycogen accumulation in multiple tissues
with a predilection for the skeletal muscle [1]. Depend-
ing on the age of onset, two different clinical forms have
been described: infantile and late-onset [2]. Late-onset
Pompe disease (LOPD) is a slowly progressive form as-
sociated with a residual enzyme activity, which presents
with either juvenile or adult onset and shows various
clinical phenotypes [3, 4].
Early clinical manifestations of LOPD are usually pro-
gressive muscle weakness and/or respiratory failure [5].
In contrast to what happens in other hereditary neuro-
muscular diseases, in which respiratory failure occurs
after the loss of ambulation, respiratory involvement in
LOPD may represent the first clinical manifestation of
the disease itself, so that patients may have respiratory
disorders despite retaining ambulation [6]. Approxi-
mately one third of adult patients affected by Pompe dis-
ease have an early respiratory phenotype, with a clinical
picture that includes dyspnea and/or respiratory failure,
sleep-disordered breathing (SDB) and recurrent pulmon-
ary infections [6]. Acute respiratory failure requiring
mechanical ventilation in Intensive Care Units (ICU) or
in Respiratory High Dependency Care Units (RHDCU)
may be the first clinical presentation of the disease [7].
However, LOPD with a prevalent respiratory derange-
ment is not easily and promptly identified during an
acute respiratory failure episode because the critical ill-
ness itself doesn’t allow a clearly diagnostic electromyo-
graphic study [8].
Enzyme replacement therapy (ERT) with alglucosidase
alpha was approved for LOPD because it can stabilize
lung function and improve walking distance [9]. More-
over, ERT may remarkably reduce muscle lysosomal
glycogen [10] and also the mortality rate compared to
untreated patients [11]. Therefore, a timely diagnosis
and establishment of ERT is associated with maximized
clinical benefit [12].
Recently, the simple measurement of GAA activity in
a dried blood spot (DBS) was proposed as a screening
method [13]. We hypothesize that the pneumologists
could play a pivotal role in the diagnosis of LOPD by ap-
plying the DBS technique. Thus, we organized a national
DBS-based screening study in the pneumological field.
Methods
The Italian Association of Hospital Pneumologists
(AIPO) selected 19 pneumological centres distributed in
almost every region of Italy with recognized experience
in the management of patients affected by neuromuscu-
lar disorders and respiratory derangement.
We performed a multicenter DBS-based case-finding
study of consecutive patients with suspected LOPD ac-
cording to a predefined clinical algorithm (Fig. 1), as de-
termined during the pneumological visit or admission to
the respiratory unit [14]. The inclusion criteria were:
age ≥ 18 yrs. and < 80 yrs., the suspicion of a neuromus-
cular disorder with respiratory involvement according to
5 + 2 items by Ambrosino et al. [14]:
1) Restrictive ventilatory deficiency (reduced FVC with
normal FEV1/FVC)
2) Nightime hypoventilation (HbO2 < 90% for more
than 5 consecutive minutes during cardiopulmonary
monitoring
3) Hypoxemia and hypercapnia at ABG
4) Weakness of the respiratory muscles (MIP, MEP,
PCEF)
5) Chest X-ray/CTscan/ultrasound significant for
diaphragm palsy, atelectasis, etc.
6) Weakness of the scapular and/or pelvic girdle
(facultative)
7) Increased blood creatin phosphokinase level
(facultative).
At least five major criteria should be present for
study inclusion, or alternatively four out of the first
five major criteria plus at least one of the facultative
criteria 6) and 7).
The exclusion criteria were: age < 18 yrs. and ≥ 80 yrs.,
presence of any already known neuromuscular disorder,
previous or current ERT, presence of clinically apparent
cardiac involvement, presence of conditions already
explaining the inclusion criteria (e.g. heart failure, COPD
ot chronic obstructive pulmonary disease, OSA or ob-
structive sleep apnea, overlap syndrome, post-surgical
respiratory failure, post-ICU, hypoventilation-obesity
syndrome, fibrothorax, diaphragm palsy of known origin,
pulmonary fibrosis, endocrine diseases).
The DBS test was performed by half a drop of blood
from a finger prick or from a venous blood sample. The
blood drop was collected on absorbent paper and the
enzyme activity was assessed in a diagnostic laboratory
as previously described [15]. Patients with GAA activity
< 2.6 μmol/L/h were considered positive. A second DBS
test (referred to as a re-test) was performed in all pa-
tients who resulted positive to the first assay. Positive
patients at the re-test underwent a confirmatory step by
determination of GAA enzymatic activity on skeletal
muscle [2]. After biochemical confirmation, a molecular
genetic analysis was performed by GAA gene sequencing
to assess the genotype of patients with LOPD.
Ethical approval was given both centrally and at each
individual centre. Patients gave written informed con-
sent. All data are presented as mean ± standard deviation
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(SD). Data analysis was performed using the GraphPad
Prism version 6 software (San Diego, CA, USA). Data
are presented as mean (SD) or median (min., max.), as
appropriate. The positive and negative predictive values
were computed from a 2 × 2 contingency table. The as-
sociation between categorical variables was evaluated
using Fisher’s exact test. Differences between groups
were assessed using the Student’s t test.
Results
The study lasted from February 2015 to December 2017
and recruited 140 patients in 16 out of 19 Italian pneumo-
logical participating units with good experience in respira-
tory failure of neuromuscular origin. Two DBS-positive
cases (patients positive in both the test and re-test) were
found and confirmed to be LOPD. The cDNA mutations
were respectively c.-32-13 T >G (IVS1); c.1564C >G
(p.Pro522Ala) and c.32-13 T >G; c.-673C > T. The charac-
teristics of the recruited patients and the two LOPD con-
firmed patients are described in Table 1.
There were a further five subjects which tested posi-
tive in the first DBS test, but were not positive at the
re-test. One of these cases could not be retested due to
death, seemingly as a result of respiratory failure (the
relatives did not authorized autopsy). In the studied
population 80 patients were male and 60 were female;
the median age at recruitment was 58 years (min.18-
max.86). The two positive cases were both diagnosed
after hospitalization in RHDCU for an acute respiratory
failure with need of noninvasive ventilation and cough
assist devices, although they had reported symptoms
(dyspnea on exertion, fatigue, sleep disturbances with
somnolence during the day, upper and lower girdle
weakness with an initial waddling gait and mild
hyperlordotic lumbar spine) for at least one year be-
fore (mean 1.2 ± 2). Other 63 patients were recruited
during hospital admission, while the remaining 75 pa-
tients underwent ambulatory pneumological visit for
respiratory symptoms.
The muscle activity of GAA in the two LOPD patients
were 3.6 pmol/min/mg and 9.1 pmol/min/mg. Among
the patients admitted to the hospital, 59 out of them re-
quired monitoring in a RHDCU, with need of noninva-
sive ventilation in 31 cases (52.5%). All the recruited
patients presented respiratory symptoms, and in fact, the
most commonly reported symptoms by the recruited
subjects were dyspnoea (121 patients, 86.4% of cases), fa-
tigue (118 patients, 84.3% of cases), orthopnea (61 pa-
tients, 43.5% of cases), and further unspecific symptoms
with overlapping frequency in our unconfirmed or posi-
tive patients. Most of the patients had reduced maximal
respiratory pressures (MIP 50 ± 27% predicted, MEP 55
± 27% predicted), and restrictive pattern (FEV1/FVC
81.3 ± 13.6) with mild hypoxaemia (PaO2 70.9 ± 14.5
mmHg). Less than half of the recruited subjects had
mild to moderate muscular symptoms including weak-
ness in the pelvic girdle (48.6%) and/or in the scapular
girdle (35.7%). There was no adverse effect or delayed
Fig. 1 Clinical algorithm to select patients for DBS test
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diagnosis due to the administration of the DBS GAA
activity test. The prevalence of DBS+ subjects in our se-
lected population was 4.2%, while the prevalence of
confirmed LOPD patients was1.4%. No association be-
tween categorical variables was found. The sensitivity
of DBS test in our population was 100%, and the speci-
ficity 97.1%. The positive predictive value (PPV) of the
DBS test in the selected patient population was 0.333
(33.3%), and the negative predictive value (NPV) was
1.000 (100%).
Discussion
A timely diagnosis and treatment of LOPD is important
to improve outcome [10], but latency from the onset of
symptoms to an established diagnosis may be up to 5–
30 years from the onset of symptoms [16, 17]. The delay
of LOPD diagnosis is mainly due to the very low inci-
dence (estimated 1 case in 57,000–100,000 in European
countries) [18, 19], together with overlapping symptoms
with other NMD [3, 18], but also the so-called “respira-
tory phenotype” might be a confounder [4]. Our national
DBS-based screening study demonstrated that also in
the pneumological setting it is possible to easily detect
patients with undiagnosed LOPD after a patient selec-
tion by means of a dedicated clinical algorithm. Particu-
larly, the late-onset form of glycogen storage disease
type II or Pompe disease (LOPD) may be suspected in
subjects with acute respiratory insufficiency, SDB and
Table 1 Clinical characteristics of the patients
Characteristics Recruited patients LOPD patient #1 LOPD patient #2
Gender, M/F 80 M/60 F M F
Age at recruitment, mean ± SD 57 ± 16 69 42
Months from symptoms onset, median (min, max) 6 (0–373) 12 16
Body mass index, kg/m2 28.5 ± 9.5 19.7 23.3
Respiratory symptoms 100% yes yes
• Dyspnea during exercise 86.4% yes yes
• Dyspnea at rest 35.9% no yes
• Ineffective cough 41.1% yes yes
• Ortopnea 43.5% no no
• Fatigue 84.3% yes yes
• Airways infections 44.1% no yes
Sleep disorders 36.4% yes yes
• Nocturnal restlessness 44.2% yes yes
• Frequent reawaken 40.0% no yes
• Nocturnal apnoea 41.4% no no
• Snoring 30.0% no no
• Morning sleepiness 25.0% no yes
• Morning headache 20.0% yes no
• Day sleepiness 39.2% yes yes
Acute respiratory failure at recruitment 28.5% yes yes
Myalgia 52.1% no no
CPKaemia, IU/L 345 ± 700 206 471
AST, U/L 27 ± 13 44 56
PaCO2, mmHg 43 ± 12 54.2 46
Upright FVC % predicted 67 ± 25 62 66
△Upright-Supine FVC% −18 ± 20 −28 −31
Lower-girdle muscle weakness, % 48.6% yes yes
Upper-girdle muscle weakness, % 35.7% yes yes
Walton&Gardner-Medwin Scale 2.9 ± 3.1 7 4
GAA activity, microMol/L/h 10.1 ± 6.6 0.36 0.71
M males, F females, CPK creatinphosphokinase, AST aspartate transaminase, PaCO2 arterial partial pressure carbon dioxide, FVC forced vital capacity, GAA
alpha glucosidase
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proximal muscle weakness without a clinically appar-
ent cardiac involvement. In our study, both of the
two patients found to have LOPD has displayed re-
spiratory and neurologic symptoms for more than 1
year, but they were detected only during an episode
of acute respiratory failure with the need of RHDCU
admission. This latency of the diagnosis may seem
too high, but it is much less than other literature re-
ports [8, 16, 17]. In line with our results, Kishnani et
al. [19] recently reported that patients with early re-
spiratory involvement can be diagnosed sooner than
those presenting with only muscular symptoms and/
or hyperCPKaemia.
Considering all the subjects included in our survey,
most of them had outpatient access, while the other pa-
tients were admitted to the hospital with access to the
emergency room (ER). Among the 65 patients admitted
to the ER, most of them required monitoring in a
RHDCU and noninvasive ventilatory support. This is
concordant with the findings of the last Italian RHDCU
survey, which highlighted the increased number of ad-
missions for acute respiratory failure of neuromuscular
origin as compared to the previous national census [20].
Nevertheless, most of the patients in our national
screening study were recruited as outpatients visited by
a pneumologist for a common symptom like exercise
dyspnoea jointly with SDB and a suspected NMD. The
execution of a DBS test for the detection of LOPD
showed high sensitivity and specificity, without disturb-
ing the correct diagnosis, or harming the patient. The
re-test did not confirm four DBS+ subjects at the first
test, but this did not influence the respiratory manage-
ment. One of the two LOPD cases presented only
slightly increased blood creatine phosphokinase (CPK)
levels (206 IU/L), supporting the observation that CPK
levels are almost normal in some cases of LOPD with re-
spiratory phenotype without limb-girdle syndrome [4, 6,
7]. Balancing the potential harms and benefits of diag-
nosing LOPD in the pneumological setting is not a con-
tentious issue as there are disease-modifying treatments
for Pompe disease, and a formal diagnosis may only
benefit every patient.
Conclusions
Testing GAA activity by DBS was shown to be a power-
ful screening tool for pneumologists, particularly in the
acute setting. A simple clinical algorithm may help the
selection of patients to administer the DBS test in order
to diagnose LOPD. Particular attention should be paid
when a patient with suspected but undiagnosed NMD
and acute respiratory failure without cardiac involve-
ment needs mechanical ventilation and/or cough assist
devices.
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